Patients with multiple sclerosis resisted to glucocorticoid therapy: abnormal expression of heat-shock protein 90 in glucocorticoid receptor complex

Abstract

Objective

The majority of patients with multiple sclerosis (MS) respond favorably to glucocorticoids (GS) for their relapse treatment (steroid-sensitive multiple sclerosis). Unfortunately, a small subset of patients with multiple-sclerosis fails to adequately respond even to high dose of GS (steroid-resistant multiple sclerosis). Mechanism of GS therapeutic unresponsiveness is not resolved.

Methods

Transcripts for glucocorticoid receptor (GR) was assessed in peripheral blood mononuclear cells by real-time polymerase chain reaction in patients with steroid-sensitive and steroid-resistant multiple sclerosis. GR expression was assessed by Western blotting. The amount of heat-shock protein 90 (hsp90) in GR cytoplasmic complex was assessed by immunoprecipitation. Hsp90 was shown to stabilize the GR complex, to prevent its translocation to nucleus, and to inhibit GR transcription.

Results

Peripheral blood mononuclear cells of steroid-resistant multiple sclerosis transcripts for all three isoforms of GR, α, β, and γ, were reduced by about two-folds compared with patients with steroid-sensitive multiple sclerosis. We have not found an increase in the β and γ transcripts of GR, which might serve as a dominant negative mutants, over GR α in steroid-resistant multiple sclerosis. The amount of hsp90 in the GR complex in cytoplasm was significantly higher in steroid-resistant multiple sclerosis compared with steroid-sensitive multiple sclerosis.

Conclusions

Molecular mechanism of GS unresponsiveness in some patients with multiple sclerosis might be related to increased presence of hsp90 in the GR cytoplasmic complex, leading to the inhibition of GR translocation to nucleus and reduction in its transcription.

Keywords

glucocorticoid receptors glucocorticoid resistance multiple sclerosis heat-shock protein 90 complex

Get full access to this article

View all access options for this article.

References

1 Confavreux C Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606–616.

2 Milligan NM Newcombe R Compston DA . A double-blind trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511–516.

3 Sloka JS Stefanelli M . The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005; 11: 425–432.

4 Reichardt HM Gold R Luhder F . Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert Rev Neurother 2006; 6: 1657–1670.

5 Leung DY Spahn JD Szefer SJ . Immunologic basis and managmnet of steroid-resistant asthma. Allergy Asthma Roc 1999; 20: 9–14.

6 Norman M Hearing SD . Glucocorticoid resistance: what is known. Cur Opin Pharmacol 2002; 2: 723–729.

7 Lanc SJ Lee TH . Corticosteroid resistance in other disease states and tissues. Am J Respir Crit Care Med 1996; 154(suppl): S62–S65.

8 Ito K Chung KF Adcock IM . Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006; 117: 522–543.

9 Hollenberg SM Weinberger C Ong ES . Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635–641.

10.

10 Leung DYM Hamid Q Vottero A . Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997; 186: 1567–1574.

11.

11 Oakley RH Jewell CM Yudt MR Bofetiado DM Cidlowski JA . The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 1999; 274: 27857–27866.

12.

12 Rivers C Levy A Hancock J Lightman S Norman M . Insertion of an amino acid in the DNA-binding domain of the glucocorticoid receptor as a result of alternative splicing. J Clin Endocrinol Metab 1999; 84: 4283–4286.

13.

13 Moalli PA Pillay S Krett NL Rosen ST . Alternatively spliced glucocorticoid receptor messenger RNAs in glucocorticoid-resistant human multiple myeloma cells. Cancer Res 1993; 53: 3877–3879.

14.

14 Beger C Gerdes K Lauten M . Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approch. Br J Haematol 2003; 122: 245–252.

15.

15 Pratt WB . The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor. J Biol Chem 1993; 268: 21455–21458.

16.

16 Rajapandi T Greene LE Eisenberg E . The molecular chaperones Hsp90 and Hsp70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor. J Biol chem 2000; 275: 22597–22604.

17.

17 Tissing WJE Meijerink JPP den Boer ML Pieters R . Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 2003; 17: 17–25.

18.

18 Haarman EG Kaspers GJL Pieters R Rottier MMA Veerman AJP . Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticoid resistance in childhood leukemia. Leukemia 2004; 18: 530–537.

19.

19 Adcock JM Lanc SJ . Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003; 178: 347–355.

20.

20 McDonald WI Compston A Edgan G Goodkin D Hartung HP . Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

21.

21 Correale J Gilmore W Li S . Resistance to glucocorticoid-induced apoptosis in PLP peptide-specific T cell clones from patients with progressive MS. J Neuroimmunol 2000; 109: 197–210.

22.

22 De Rijk RH Eskandari F Stenberg EM . Corticosteroid resistance in a subpopulation of multiple sclerosis patients as measured by ex vivo dexamethasone inhibition of LPS induced Il-6 production. J Neuroimmunol 2004; 151: 180–188.

23.

23 Van Winsen LLM Hooper-van Veen T van Rossum EFC . The impact of glucocorticoid receptor gene polymorphisms on glucocorticoid sensitivity is outweighted in patients with multiple sclerosis. J Neuroimmunol 2005; 167: 150–156.

24.

24 Spahn JD Landwehr LP Nimmagadda S Surs W Leung DYM Szefler SJ . Effect of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. J Allergy Clin Immunol 1996; 98: 1073–1079.

25.

25 Sionov RV Kfir S Zafrir E Cohen O Zilberman Y Yefenof E . Glucocorticoid-induced apoptosis revisited: a novel role for glucocorticoid receptor translation to the mitochondria. Cell Cycle 2006; 5: 1017–1026.

26.

26 Tissing WJE Lauten M Meijerink JPP . Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childchood acute lymphocytic leukemia. Haematologica 2005; 90: 1279–1281.

27.

27 Kang KI Meng X Devin-Leclerc J . The molecular chaperone Hsp90 can negatively regulate the activity of a glucocorticoid-dependent promoter. Proc Natl Acad Sci USA 1999; 96: 1439–1444.

28.

28 Yang J DeFranco DB . Assessment of glucocorticoid receptor-heat shock protein 90 interactions in Vivo during nucleocytoplasmic trafficking. Mol Endo 1996; 10: 3–13.